In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Watson acquires Australian OTC firm; childproof packaging for imidazoline; Supplement Facts box update delayed; more news In Brief

You may also be interested in...



CHPA Requests Extension To Childproof Imidazoline Product Packaging

The OTC trade group says firms need two years, twice the time CPSC would allow under a proposed rule, to require child-resistant packaging for drugs with more than 0.08 mg of imidazolines, including such OTCs as Visine eye drops and Afrin nasal decongestants.

CHPA Requests Extension To Childproof Imidazoline Product Packaging

The OTC trade group says firms need two years, twice the time CPSC would allow under a proposed rule, to require child-resistant packaging for drugs with more than 0.08 mg of imidazolines, including such OTCs as Visine eye drops and Afrin nasal decongestants.

People In Brief

Himmel named ChromaDex CEO; Pinney reorganizes senior management; FDA vet Chappell jumps to Greenleaf; more People In Brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel